This review evaluates bioidentical hormone therapy (BHT) for managing menopausal symptoms, comparing it to conventional hormone replacement therapy (HRT). While BHT may alleviate symptoms for some, evidence supporting its efficacy and safety is limited, and there is no clear advantage over traditional HRT. The review also highlights concerns with individualized
This article explores the widespread use of compounded bioidentical hormone therapy (cBHT), highlighting the lack of rigorous scientific evidence supporting its safety and efficacy. It stresses the need for clinicians to guide patients toward FDA-approved treatments for menopausal symptoms rather than relying on unregulated compounded alternatives. The article emphasizes the
This systematic review assesses randomized controlled trials (RCTs) on the efficacy and safety of testosterone therapy for postmenopausal women with sexual dysfunction. Key findings suggest that testosterone improves sexual function and may increase bone mineral density and decrease HDL cholesterol. However, the long-term safety remains unclear. The article aims to
The article evaluates bioidentical hormone therapy (BHT), comparing it to conventional hormone therapy (CHT). While BHT is marketed as a safer alternative, the review emphasizes that there is insufficient scientific evidence to support its claimed benefits and safety. The article urges caution, as the lack of standardized formulations and proper
The article examines the use of continuous low-dose combined hormone replacement therapy (HRT) and its association with endometrial cancer risk, specifically focusing on eight cases of endometrial carcinoma. Factors such as inadequate progestin dosage, poor patient compliance, and prolonged unopposed estrogen use were found to contribute to this risk. While
This article examines the impact of estrogen replacement therapy during menopause, emphasizing its role in mitigating cardiovascular and musculoskeletal risks. It highlights the benefits of estrogen for reducing the risks of coronary heart disease and osteoporosis, particularly with transdermal forms for older women due to a lower risk of thrombosis.
This review discusses the use of bioidentical hormones for menopausal therapy, criticizing the assumption that they are safer than synthetic hormones. Despite some proponents advocating for their use, particularly through salivary hormone testing, the review finds insufficient evidence to support their superiority or safety compared to synthetic options. Providers should
The article “Designing drugs for the treatment of female sexual dysfunction” (PMID: 17826689) reviews therapeutic strategies for female sexual dysfunction (FSD), which affects approximately 30% of women and includes issues with desire, arousal, and orgasm. Early treatments, modeled after male erectile dysfunction therapies, have largely been ineffective for women, leading
This clinical trial examined how oral progesterone absorption is influenced by formulation, specifically particle size and vehicle type. Seven subjects received a 200 mg dose of progesterone in different formulations: plain milled, micronized, plain milled in oil, micronized in oil, and micronized in enteric-coated capsules. Serum progesterone levels were measured
This observational study examined the incidence of breast cancer in postmenopausal women using conventional hormone therapy (HT) with the addition of testosterone implants. The findings suggested that adding testosterone to standard HT was associated with a lower incidence of breast cancer compared to HT alone, indicating a potential protective effect.
